Eric Lawitz
Impact in
- Hepatology top 0.02%
- Hepatitis C virus research
- Liver Disease and Transplantation
- Epidemiology top 0.05%
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
Papers in
- Hepatology 205
- Hepatitis C virus research 183
- Liver Disease and Transplantation 18
- Liver Diseases and Immunity 15
- Epidemiology 148
- Liver Disease Diagnosis and Treatment 112
- Hepatitis B Virus Studies 44
- Co-authors
- John G. McHutchison (46 shared papers)Fred Poordad (44 shared papers)Stefan Zeuzem (20 shared papers)M. Rodríguez‐Torres (31 shared papers)Stuart C. Gordon (29 shared papers)Bruce R. Bacon (20 shared papers)Rohit Loomba (31 shared papers)Clifford A. Brass (18 shared papers)
- Journals
- Journal of Hepatology (89 papers)Gastroenterology (41 papers)Hepatology (24 papers)The American Journal of Gastroenterology (15 papers)Clinical Gastroenterology and Hepatology (12 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Eric Lawitz
301 papers receiving 16.7k citations
Eric Lawitz's Hit Papers
Peers
Comparison fields: 5 of 144
- Hepatology 10.7k
- Epidemiology 8.9k
- Infectious Diseases 1.8k
- Cancer Research 1.3k
- Endocrinology, Diabetes and Metabolism 1.4k
Countries citing papers authored by Eric Lawitz
This map shows the geographic impact of Eric Lawitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Lawitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Lawitz more than expected).
Fields of papers citing papers by Eric Lawitz
This network shows the impact of papers produced by Eric Lawitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Lawitz. The network helps show where Eric Lawitz may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Lawitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 322 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Treatment of HCV Infection by Targeting MicroRNA Hit paper breakdown → | 2013 | 1776 |
| 2 | Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection Hit paper breakdown → | 2011 | 1266 |
| 3 | Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection Hit paper breakdown → | 2009 | 915 |
| 4 | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Hit paper breakdown → | 2010 | 532 |
| 5 | Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1 Hit paper breakdown → | 2012 | 471 |
| 6 | The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial Hit paper breakdown → | 2017 | 449 |
| 7 | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Hit paper breakdown → | 2013 | 449 |
| 8 | Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis Hit paper breakdown → | 2024 | 443 |
| 9 | Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial Hit paper breakdown → | 2018 | 436 |
| 10 | Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial Hit paper breakdown → | 2023 | 323 |
| 11 | 2017 | 280 | |
| 12 | GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease Hit paper breakdown → | 2018 | 266 |
| 13 | A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis Hit paper breakdown → | 2024 | 264 |
| 14 | 2013 | 234 | |
| 15 | 2013 | 222 | |
| 16 | 2016 | 202 | |
| 17 | 2013 | 201 | |
| 18 | 2010 | 200 | |
| 19 | 2014 | 199 | |
| 20 | 2014 | 197 |
About Eric Lawitz
Eric Lawitz is a scholar working on Hepatology, Epidemiology, Infectious Diseases, Rheumatology and Molecular Biology, having authored 322 papers that have together received 17.1k indexed citations. Recurring topics across this work include Hepatitis C virus research (183 papers), Liver Disease Diagnosis and Treatment (112 papers), Hepatitis B Virus Studies (44 papers), HIV/AIDS drug development and treatment (35 papers), Systemic Lupus Erythematosus Research (26 papers), Liver Disease and Transplantation (18 papers), Liver Diseases and Immunity (15 papers) and Chronic Lymphocytic Leukemia Research (15 papers). The work is most often cited by research in Hepatology (10.7k citations), Epidemiology (8.9k citations), Infectious Diseases (1.8k citations), Cancer Research (1.3k citations) and Endocrinology, Diabetes and Metabolism (1.4k citations). Eric Lawitz has collaborated with scholars based in United States, France and Germany. Frequent co-authors include John G. McHutchison, Fred Poordad, Stefan Zeuzem, M. Rodríguez‐Torres, Stuart C. Gordon, Bruce R. Bacon, Rohit Loomba, Clifford A. Brass, Janice K. Albrecht and Zachary Goodman. Their work appears in journals such as Journal of Hepatology, Gastroenterology, Hepatology, The American Journal of Gastroenterology and Clinical Gastroenterology and Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.